0 seconds of 2 minutes, 32 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
02:32
02:32
 
  • SQI Diagnostics (SQD) has received Health Canada Interim Order authorization for its Rapid Acute Lung Injury Diagnostic (RALI-Dx) IL-6 Severity Triage Test
  • RALI-Dx is the first interleukin-6 (IL-6) diagnostic test approved in Canada
  • SQI CEO Andrew Morris sat down with Daniella Atkinson to discuss the news
  • SQI Diagnostics Inc is a Canada-based company engaged in developing and commercializing technologies & products for multiplexing diagnostics
  • SQI Diagnostics opened trading at C$0.105

SQI Diagnostics (SQD) has received Health Canada Interim Order authorization for its Rapid Acute Lung Injury Diagnostic (RALI-Dx) IL-6 Severity Triage Test.

RALI-Dx is the first interleukin-6 (IL-6) diagnostic test approved in Canada, and its turnaround time of less than an hour is developed to fill an important and unmet public health need.

SQI Diagnostics CEO Andrew Morris sat down with Daniella Atkinson to discuss the news.

“COVID continues to strain our health care system, continues to spawn new variants and continues to be a challenge as new waves continue to form,” said Andrew Morris, President and CEO of SQI Diagnostics.

“We believe RALI-Dx will be an important tool in the hands of Emergency Room doctors to help raise survival rates for the most seriously ill COVID patients while also improving the efficiency and efficacy of hospital care. We also hope to investigate its potential use in other severe respiratory health conditions.”

The Severity Triage test is intended to play a vital role in clarifying COVID-19 patient risk. By testing for the presence of the key bio-marker IL-6, RALI-Dx helps identify which patients are most at risk of a severe inflammatory response from cytokine storms, which is associated with the worst patient outcomes.

SQI Diagnostics is a Canada-based company engaged in developing and commercializing technologies & products for multiplexing diagnostics.

SQI Diagnostics Inc. (SQD) opened trading at C$0.105.

Latest Bullboard Posts
More From The Market Online
ai generated stock image

@ the Bell: Markets stumble into the weekend

Canada’s main stock index faced challenges on Friday as commodity prices declined and mixed signals from US-China trade discussions.
ai generated stock image

@ the Bell: Ongoing tariff drama erodes market confidence

Canada’s main stock index was subdued on Thursday as traders assessed risks of the US administration's fluctuating stance on tariffs.
BriaCell logo

BriaCell’s Bria-OTS shows sustained success against breast cancer

BriaCell (TSX:BCT) announces the resolution of the lung metastasis first reported in February in a 78-year-old woman with breast cancer.
The Market Online Video

Trade Wars, Soaring Gold, and Canada’s Political Crossroads

The Canadian Securities Exchange presents your go-to source for trends in junior and small cap markets each month.